SMARCB1 and chordoma: Some trials are currently evaluating clinical efficacy of an EZH2 inhibitor named Tazemetostat in patients with poorly differentiated chordoma with SMARCB1 loss (NCI# NCT02601950 and NCT02601937) (138).